Ventilator Care — Cost, Top Hospitals & Success Rates | MyMedicPlus

Mechanical ventilator care involves the use of a ventilator — a device that partially or fully takes over the work of breathing — to support or replace spontaneous respiration in patients whose lungs or respiratory muscles cannot maintain adequate gas exchange. Invasive mechanical ventilation requires insertion of an endotracheal tube (intubation) into the trachea, connected to a ventilator circuit, while non-invasive ventilation (NIV) delivers positive pressure through a tight-fitting face or nasal mask. Ventilator care is delivered exclusively in an Intensive Care Unit (ICU) or high-dependency unit (HDU) environment, requiring round-the-clock monitoring by critical care nurses, respiratory therapists, and intensivists.

The goals of mechanical ventilation are twofold: to correct arterial hypoxaemia (low blood oxygen, PaO2) and hypercapnia (elevated carbon dioxide, PaCO2) while simultaneously protecting the lungs from ventilator-induced lung injury (VILI). VILI occurs when high tidal volumes, high inflation pressures, or high fractions of inspired oxygen (FiO2) further damage already injured lung tissue — a phenomenon described as barotrauma, volutrauma, atelectrauma, and biotrauma. Lung-protective ventilation, derived from the landmark ARDSnet trial (2000), uses low tidal volumes (6 mL/kg ideal body weight) and restricts plateau pressure to below 30 cmH2O to minimise this injury.

The clinical journey on mechanical ventilation proceeds from intubation and initial ventilator setup, through optimisation of settings based on arterial blood gas results and lung mechanics, to a systematic weaning process once the underlying condition improves. Daily spontaneous awakening trials (SAT) — temporarily discontinuing sedation — combined with spontaneous breathing trials (SBT) are the evidence-based approach to determining readiness for extubation. Ventilator care for prolonged periods (beyond 14–21 days) typically requires surgical tracheostomy to improve patient comfort and facilitate weaning.

Mechanical ventilation is indicated for any patient who cannot maintain adequate respiratory function independently. Acute respiratory distress syndrome (ARDS) — characterised by bilateral lung infiltrates, severe hypoxaemia (PaO2/FiO2 ratio below 300), and non-cardiac aetiology — is the most common critical care condition requiring lung-protective mechanical ventilation. Severe pneumonia, including COVID-19-associated respiratory failure, often progresses to ARDS requiring prolonged ventilation. Acute exacerbations of chronic obstructive pulmonary disease (COPD) with hypercapnic respiratory failure are frequently managed with non-invasive positive pressure ventilation (BiPAP) as a first step, with intubation reserved for NIV failure.

Severe asthma unresponsive to nebulised bronchodilators and systemic steroids may require ventilator support, with specialised strategies to manage dynamic hyperinflation and high airway pressures. Neurological conditions — including severe traumatic brain injury, high cervical spinal cord injury, Guillain-Barré syndrome, and myasthenic crisis — cause respiratory failure through loss of central respiratory drive or neuromuscular weakness, requiring ventilation often for extended periods. Post-operative ventilator care is routine after major cardiac and thoracic surgery. Drug overdose with respiratory depression, pulmonary oedema from cardiac failure, and smoke inhalation injury round out the major indications for ventilator care.

Indications for mechanical ventilation include apnoea, severe hypoxaemia (SpO2 below 88–90% despite high-flow supplemental oxygen), respiratory acidosis (pH below 7.25 with rising PaCO2), rapidly increasing work of breathing with use of accessory muscles and paradoxical breathing, declining level of consciousness compromising airway protection, and shock states where respiratory muscles compete for limited cardiac output. Non-invasive ventilation (NIV with CPAP or BiPAP) may be tried as a less invasive initial approach in appropriate patients: those with hypercapnic COPD exacerbation, cardiogenic pulmonary oedema, or post-extubation respiratory failure, provided they are awake, cooperative, and haemodynamically stable.

Contraindications to NIV that necessitate invasive mechanical ventilation include inability to protect the airway (reduced GCS), facial trauma precluding mask fitting, high-risk aspiration, haemodynamic instability unresponsive to fluids, and conditions requiring definitive airway management for surgery. Patients with documented advance directives against mechanical ventilation, terminal illness where ventilation prolongs dying rather than supporting recovery, or those for whom a palliative care plan has been agreed upon should not be intubated; instead, comfort-focused opioid and anxiolytic management of breathlessness is appropriate. These decisions require honest family communication and ideally involve specialist palliative care teams.

Ventilator modes are the fundamental treatment variable. Volume-controlled ventilation (VCV) delivers a set tidal volume with each breath, while pressure-controlled ventilation (PCV) delivers a set driving pressure. Pressure support ventilation (PSV) augments the patient's own spontaneous breaths and is used during weaning. Synchronised intermittent mandatory ventilation (SIMV) provides a set number of mandatory breaths while allowing patient-triggered additional breaths. For ARDS, lung-protective VCV with tidal volume 6 mL/kg ideal body weight, PEEP 5–15 cmH2O (titrated to achieve oxygenation targets without causing haemodynamic compromise), and FiO2 as low as needed to maintain SpO2 of 88–95% constitutes the standard of care.

For refractory ARDS (PaO2/FiO2 below 150), rescue strategies include prone positioning (16–18 hours per day reduces mortality by approximately 16% per the PROSEVA trial), neuromuscular blockade to improve patient-ventilator synchrony, recruitment manoeuvres to open collapsed alveoli, and, in the most severe cases, venovenous extracorporeal membrane oxygenation (VV-ECMO) which bypasses the lungs entirely by oxygenating blood extracorporeally. High-frequency oscillatory ventilation (HFOV) is no longer routinely recommended after neutral trials (OSCILLATE, OSCAR). Non-invasive high-flow nasal cannula oxygen (HFNO) therapy — delivering 30–60 L/min of heated, humidified, high-FiO2 gas — is an intermediate step between standard oxygen therapy and intubation, successfully avoiding intubation in a proportion of patients.

Mechanical ventilation is life-saving for patients with acute respiratory failure who would otherwise die of hypoxaemia or respiratory exhaustion. Lung-protective ventilation per the ARDSnet protocol reduces 28-day mortality in ARDS from approximately 40% (with traditional high-volume ventilation) to approximately 31%, a clinically significant improvement representing thousands of lives saved annually. Prone positioning in moderate-severe ARDS reduces mortality from approximately 33% to 16% (PROSEVA trial). VV-ECMO for severe ARDS (RESP score >5) can achieve survival rates of 65–70% in carefully selected patients at experienced ECMO centres.

For non-ARDS indications, outcomes are generally more favourable. Post-operative ventilation after major cardiac surgery is typically discontinued within 4–8 hours in uncomplicated cases. NIV for COPD exacerbation avoids intubation in approximately 60–70% of patients, reducing ICU length of stay and mortality. Neuromuscular disease patients on ventilatory support can be maintained long-term on home mechanical ventilation — either invasively via tracheostomy or non-invasively — enabling community living. Successful weaning and extubation after the underlying condition resolves returns patients to independent breathing in the majority of cases, with complete recovery of respiratory function achievable for conditions such as pneumonia, pulmonary oedema, and drug-induced respiratory depression.

Ventilator-induced lung injury (VILI) is the most significant inherent risk of mechanical ventilation, potentially worsening the very lung disease it supports if ventilation parameters are not carefully controlled. Ventilator-associated pneumonia (VAP) occurs in 5–20% of intubated patients per 1,000 ventilator days and is associated with increased ICU mortality, length of stay, and healthcare costs. Prevention bundles — elevation of the head of bed to 30–45 degrees, daily oral care with chlorhexidine, sedation minimisation, and aspiration precautions — substantially reduce VAP incidence.

Pneumothorax from barotrauma can occur when high inflation pressures rupture alveoli, requiring urgent chest drainage. Prolonged intubation causes upper airway trauma, tracheal stenosis (in up to 10% of patients ventilated beyond 7–10 days), and sinusitis. Haemodynamic compromise from positive pressure ventilation — which reduces venous return and cardiac preload — is particularly significant in volume-depleted patients and those with right heart failure. ICU-acquired weakness (ICUAW), a combination of critical illness myopathy and polyneuropathy, affects up to 60% of patients ventilated for more than 7 days, leading to prolonged weaning, delayed extubation, and protracted physical rehabilitation.

Weaning from mechanical ventilation follows a structured protocol. Once the underlying acute condition has resolved or sufficiently improved, the spontaneous breathing trial (SBT) evaluates whether the patient can sustain breathing independently on minimal support (T-piece or pressure support of 5–8 cmH2O for 30–120 minutes). Successful SBT followed by adequate cough, secretion management, and intact swallowing reflex enables extubation. Patients who fail multiple SBTs may require percutaneous dilatational tracheostomy at day 10–14, which facilitates ventilator weaning, reduces sedation requirements, and enables oral feeding and communication via speaking valves.

After extubation, physiotherapy focuses on airway clearance, incentive spirometry, and gradual mobilisation. High-flow nasal oxygen or NIV may bridge the immediate post-extubation period in at-risk patients. Post-ICU follow-up at 4–6 weeks evaluates pulmonary function, respiratory symptoms, and the presence of post-intensive care syndrome (PICS) — which encompasses cognitive impairment, psychological distress, and physical deconditioning. Patients ventilated for more than 2 weeks typically require several months of rehabilitation. Pulmonary function tests at 3–6 months are recommended for ARDS survivors, with significant impairment present in up to 50% at 1 year that gradually improves over 2–5 years.

Mechanical ventilation is one of the most resource-intensive components of intensive care. In the United States, ICU care with mechanical ventilation costs $3,000–$5,000 per day, with average 7-day ventilator episodes totalling $20,000–$35,000 and prolonged ventilation exceeding $150,000. In the United Kingdom under the NHS, ICU ventilator care costs approximately £1,500–£2,500 per day; private ICU rates are considerably higher. Total costs for a ventilated ARDS episode in the UK private sector can exceed £30,000–£80,000 depending on duration and complexity.

Patients requiring elective prolonged ventilator weaning — after initial acute phase management — or ventilator-dependent neurorehabilitation after spinal cord injury can access equivalent care at significantly lower cost in countries like India, Thailand, and Turkey. JCI-accredited ICUs in India charge $300–$700 per ventilator day, making a 14-day weaning episode $5,000–$10,000 versus $40,000–$70,000 in the US. Home ventilator care for neuromuscular disease patients — using BiPAP or volume-cycled home ventilators — is substantially lower cost in all countries and enables patients to live at home rather than in long-term care facilities.

The primary alternative to invasive mechanical ventilation for appropriate patients is non-invasive positive pressure ventilation (NIV), delivered as CPAP or BiPAP via a tight-fitting mask. NIV avoids the risks of intubation — tracheal injury, VAP, and the need for sedation — and is the treatment of choice for COPD exacerbation and acute cardiogenic pulmonary oedema, where it is equally effective to invasive ventilation in avoiding mortality in well-selected patients. High-flow nasal cannula (HFNC) oxygen therapy provides humidified high-FiO2 gas at high flow rates, reducing work of breathing and improving oxygenation in acute hypoxaemic respiratory failure, potentially avoiding the need for escalation to invasive ventilation in approximately 40–50% of patients.

For patients with chronic respiratory failure who are not acutely decompensating, long-term domiciliary NIV using a home BiPAP machine overnight or for a set number of hours daily can prevent acute exacerbations and hospital admissions, as demonstrated in COPD patients with chronic hypercapnia (HOT-HMV trial). For neuromuscular disease patients (ALS, Duchenne muscular dystrophy), nocturnal NIV initiated early in the disease course prolongs survival and maintains quality of life. Palliative use of opioids and benzodiazepines to relieve dyspnoea without intubation is the appropriate alternative for patients where ventilation would only prolong the dying process.